Medicine
Egrifta SV kit
Egrifta SV kit is a prescription medicine containing Tesamorelin for subcutaneous use, marketed by Theratechnologies, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store EGRIFTA SV 2 mg vial at room temperature at 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Tesamorelin
- Brand
- Egrifta SV
- Dosage form
- Kit
- Route
- Subcutaneous
- Packs
- 1 kit
- Marketing authorisation holder
- Theratechnologies
- Manufacturer
- Theratechnologies
- Origin register
- US FDA, United States
- Storage
- Store EGRIFTA SV 2 mg vial at room temperature at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store the Injection box (containing Sterile Water for Injection, syringes and needles) at room temperature at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01AC06 Tesamorelin
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 November 2019
- Identifiers
- RxCUI 1044587, 1044591DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224NDC 62064-241Application BLA022505
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 box * .5 mL in 1 vial * 30 bottle in 1 tray / 10 mL in 1 bottle | 62064-241-30 | Theratechnologies | 4 November 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 November 2010 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tesamorelin kit.
Clinical summary
Tesamorelin is a prescription medicine indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, among other approved uses. It is available as kits for subcutaneous use. MedsAcross supplies Tesamorelin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TesamorelinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EGRIFTA SV prescribing information (Theratechnologies) · U.S. National Library of Medicine, DailyMed
Need Egrifta SV kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.